Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Leupeptin hemisulfate (HB3958)
Description:Reversible trypsin-like and cysteine proteases inhibitor
Purity:>97%
MEGA-8 (HB3972)
Description:Non-ionic,water-soluble detergent with nondenaturing properties
Purity:>99%
Mifepristone (HB2783)
Description:Potent glucocorticoid and progesterone receptor antagonist. Also used for gene editing as a mifepristone inducible Cas9 and Cpf1 CRISPR effector.
Purity:>99%
(+)-MK 801 maleate (HB0004)
Description:Potent, selective, non-competitive NMDA receptor antagonist
Purity:>98%
MOG (35-55) (HB5273)
Description:Myelin oligodendrocyte glycoprotein fragment. Induces experimental multiple sclerosis-like disease.
Purity:>95%
Monensin sodium salt (HB4882)
Description:Protein transport inhibitor. Commonly used in cytokine staining.
Purity:>98%
MPEP hydrochloride (HB0426)
Description:Potent, selective mGluR5 antagonist / mGluR4 positive allosteric modulator
Purity:>98%